HC Wainwright Forecasts Strong Price Appreciation for DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) had its target price boosted by equities researchers at HC Wainwright from $7.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price target would suggest a potential upside of 100.80% from the company's previous close. HC Wainwright also issued estimates for DiaMedica Therapeutics' Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.46) EPS and FY2029 earnings at $0.06 EPS.

DiaMedica Therapeutics Price Performance

Shares of DMAC traded down $0.16 during trading hours on Wednesday, hitting $4.98. The stock had a trading volume of 74,684 shares, compared to its average volume of 69,352. The firm has a 50 day simple moving average of $5.93 and a 200-day simple moving average of $5.13. The firm has a market capitalization of $212.95 million, a P/E ratio of -8.89 and a beta of 1.52. DiaMedica Therapeutics has a 1-year low of $2.14 and a 1-year high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Equities analysts predict that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.

Remove Ads

Institutional Trading of DiaMedica Therapeutics

Several large investors have recently made changes to their positions in the company. Susquehanna International Group LLP boosted its stake in DiaMedica Therapeutics by 269.5% during the 4th quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock valued at $2,035,000 after purchasing an additional 273,395 shares during the last quarter. 683 Capital Management LLC acquired a new position in DiaMedica Therapeutics during the 4th quarter valued at about $413,000. Geode Capital Management LLC boosted its stake in DiaMedica Therapeutics by 29.6% during the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company's stock valued at $1,286,000 after purchasing an additional 70,070 shares during the last quarter. Northern Trust Corp boosted its stake in DiaMedica Therapeutics by 49.8% during the 4th quarter. Northern Trust Corp now owns 180,192 shares of the company's stock valued at $978,000 after purchasing an additional 59,902 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in DiaMedica Therapeutics by 151.8% during the 4th quarter. Millennium Management LLC now owns 84,829 shares of the company's stock valued at $461,000 after purchasing an additional 51,139 shares during the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.